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Background: Totally implantable venous access port (TIVAP) implantation is one of the most often performed
operations in general surgery (over 100,000/year in Germany). The two main approaches for TIVAP placement are
insertion into the cephalic vein through an open cut-down technique (OCD) or closed cannulation technique of
the subclavian vein (CC) with Seldinger technique. Both procedures are performed with high success rates and very
low complication frequencies. Because of the low incidence of complications, no single interventional trial is able to
report a valid comparison of peri- and postoperative complication frequencies between both techniques. Therefore,
the aim of this systematic review is to summarize evidence for peri- and postoperative complication rates in
patients undergoing OCD or CC.
Methods/Design: A systematic literature search will be conducted in The Cochrane Library, MEDLINE, and Embase to
identify randomized controlled trials (RCTs), observational clinical studies (OCS), or case series (CS) reporting peri- and/
or postoperative complications of at least one implantation technique. A priori defined data will be extracted from
included studies, and methodological quality will be assessed. Event rates with their 95% confidence intervals will be
derived taking into account the follow-up time per study by patient-months where appropriate. Pooled estimates of
event rates with corresponding 95% confidence intervals will be calculated on the base of the Freeman-Tukey double
arcsine transformation within a random effect model framework.
Discussion: The findings of this systematic review with proportional meta-analysis will help to identify the
procedure with the best benefit/risk ratio for TIVAP implantation. This may have influence on daily practice, and
data may be implemented in treatment guidelines. Considering the impact of TIVAP implantation on patients’
well being together with its socioeconomic relevance, patients will benefit from evidence-based treatment and
health-care costs may also be reduced.
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Since the introduction of totally implantable venous access
ports (TIVAP) by Niederhuber et al. in 1982, TIVAP have
been implanted routinely in patients who need a safe and
permanent venous access for repeated administration of
chemotherapy, parenteral nutrition, blood, antibiotics, and/
or analgetics [1,2]. In daily practice, TIVAP are being exten-
sively used worldwide and as implantation is a short pro-
cedure, it is performed preferably in an outpatient setting.
In the USA, every year, approximately five million central
venous catheters are inserted, whereby TIVAP are sup-
posed to represent a considerable proportion of this num-
ber. In Germany, 477,300 new cases of oncological diseases
were diagnosed in 2010 [3]. In the same year, approximately
125,790 TIVAP were performed in German hospitals and
this number is constantly increasing which may be attrib-
uted to the development of innovative neoadjuvant and ad-
juvant oncological therapies [4]. The two main approaches
for TIVAP placement are insertion into the cephalic vein
through an open cut-down technique (OCD) (Figure 1)
predominantly performed by surgeons with a median pri-
mary success rate of 80% (range 71% to 94%) in various
prospective and retrospective trials or closed cannulation
technique of the subclavian vein (CC) and insertion of the
catheter with Seldinger technique (Figure 2) mainly per-
formed by an interventional radiologist, surgeon, or anaes-
thesiologist with a median primary success rate of 90% toFigure 1 Open cut-down of cephalic vein.100% in predominantly retrospective trials [5-7]. Three
different techniques of CC are most common: first, CC
supported by ultrasound guidance; second, CC supported
by contrast agent and radiation (roadmap technique); or
third, using a blind puncture method guided by anatom-
ical landmarks (landmark technique) [2].
While common complications such as kinking or disloca-
tion of the catheter, thrombosis, subcutaneous hematoma,
and wound infection are observed in both techniques, some
specific serious risks are associated only with CC, including
‘pinch off ’ phenomena and pneumo- or hematothorax. The
latter complications in particular require further invasive
treatment, and admission to a hospital is often necessary
[8]. A recent meta-analysis of six randomized controlled
trials (RCTs) from 2014 showed a significantly higher
primary success rate for CC but with the exclusive risk of
pneumothorax occurrence [9]. In contrast, no pneumo-
thorax was found in the OCD group.
To answer the question of overall superior benefit/risk ra-
tio, not only the primary success rate but also peri- and
postoperative complication frequencies have to be taken into
account. So far, complications have been assessed as primary
endpoint in only one RCT [10]. As all other trials performed
to date are not powered for complications as primary end-
point, sample sizes of these studies may not be appropriate
for the interpretation of peri- and postoperative complica-
tions. In most trials, low adverse event rates are presented
Figure 2 Closed cannulation of subclavian vein.
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sidering the high frequency of implantations performed,
even small differences in complication rates could be highly
relevant for patients and the health-care system.
None of the existing trials had a major influence on
daily practice of TIVAP implantation [9]. As evidence
for the strategy with the best benefit/risk ratio is poor,
the choice of the technique is primarily made by the
preference of the surgeon and not evidence-based. The
aim of this systematic review and meta-analysis is to
summarize the available evidence for peri- and post-
operative complications of OCD compared to CC.
Methods/Design
The protocol of this study is written according to the
Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols 2015 (PRISMA-P 2015) [11].
As outlined in this protocol, the following methods are
planned.
Systematic literature search methodology
To identify all relevant data to the scope of this review,
the following searches will be performed. Published and
unpublished studies investigating peri- and/or postoper-
ative complications in TIVAP implantation performed
by OCD or CC will be searched for. To answer our
research question not only RCTs but also observational
clinical studies (OCS) and case series (CS) will be
searched for. Additionally, previous systematic as well as
non-systematic reviews will be consulted. To identify all
relevant studies with these characteristics, systematic lit-
erature searches will be conducted in the following data-
bases: The Cochrane Library, MEDLINE, and Embase.For each database, an appropriate search strategy will be
constructed by selecting suitable medical subject head-
ings (MeSH) and free text terms in combination with
Boolean operators. A search strategy drafted for MED-
LINE is shown below. The search will not be restricted to
language or status of the publication. Studies published
before 1982 will not be considered as in this year; Nieder-
huber et al. reported the first TIVAP implantation [1].
Search results will be exported to the reference software
program EndNote (version X7) to create a library in
which all articles will be entered. The registries in
ClinicalTrials.gov, Current Controlled Trials, and UMIN
Clinical Trials Registry, as well as PROSPERO, will be
searched to identify registered trials and reviews. Refer-
ence lists of relevant articles will be searched manually
for additional trials. Furthermore, investigators and ex-
perts in this field will be contacted. Based on preliminary
research, only very few RCTs but more than 50 OCS and
CS are expected. The following is the search strategy
drafted for MEDLINE:
‘port catheter’[tiab] OR ‘port catheters’[tiab] OR
‘port-a-cath’[tiab] OR ‘port-a-catheters’[tiab] OR ‘port
implantation’[tiab] OR ‘port implantations’[tiab] OR
TIVAP[tiab] OR TIAP[tiab] OR ‘totally implantable
port’[tiab] OR ‘totally implantable ports’[tiab] OR ‘to-
tally implantable venous access ports’[tiab] OR ‘totally
implantable venous access port’[tiab] OR ‘totally im-
plantable venous access ’[tiab] OR ‘totally implantable
access port’[tiab] OR ‘totally implantable access port-
s’[tiab] OR ‘venous port system’[tiab] OR ‘venous port
systems’[tiab] OR ‘venous access device’[tiab] OR ‘venous
access devices’[tiab] OR‘ vein access’ OR ‘vein cannulation’
OR ‘vein cannulations’ OR ‘implantable injection
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‘subcutaneous port’[tiab] OR ‘subcutaneous ports’[tiab]
OR ‘vascular access device’[tiab] OR ‘vascular access
devices’[tiab] OR ‘vascular access port’[tiab] OR ‘vascu-
lar access ports’[tiab] OR ‘infusion port’[tiab] OR ‘infu-
sion ports’[tiab] OR ‘venous cut-down technique’[tiab]
OR ‘surgical cutdown’[tiab] OR ‘cutdown technique’[tiab]
OR ‘seldinger technique’[tiab] OR ‘modified seldinger
technique’ [tiab]
AND
complications[tiab] OR ‘wound infection’[tiab] OR
‘wound infections’[tiab] OR ‘Wound Infection’[Mesh]
OR ‘Surgical Wound Infection’[Mesh] OR SSI[tiab] OR
‘surgical site infection’[tiab] OR ‘surgical site infection-
s’[tiab] OR site infection[tiab] OR infection[tiab] OR
hemothorax[tiab] OR ‘Hemothorax’[Mesh] OR hema-
tothorax[tiab] OR haematothorax[tiab] OR pnx[tiab] OR
pneumothorax[tiab] OR ‘Pneumothorax’[Mesh] OR
((dislocation OR malpositioning OR breakage) AND
(TIVAP OR TIAP OR catheter OR catheters)) OR ‘nerve
lesion’[tiab] OR ‘nerve lesions’[tiab] OR hematoma[tiab]
OR hematomas[tiab] OR haematoma[tiab] OR haemato-
mas[tiab] OR ‘Hematoma’[Mesh] OR ‘postoperative
bleeding’[tiab] OR extravasation[tiab] OR extravasation-
s[tiab] OR ‘Extravasation of Diagnostic and Therapeutic
Materials’[Mesh] OR ‘hospital readmission’[tiab] OR ‘hos-
pital admission’[tiab] OR ‘nerve lesion’[tiab] OR ‘nerve
lesions’[tiab] OR sepsis[tiab] OR ‘septic shock’[tiab] OR
‘catheter sepsis’[tiab] OR reoperation[tiab] OR ‘TIAP
explantation’[tiab] OR ‘plexus palsy’[tiab] OR ‘brachial
plexus palsy’[tiab] OR ‘arterial puncture’[tiab] OR hemop-
tysis[tiab] OR ‘Hemoptysis’[Mesh] OR ‘pinch off ’[tiab] OR
((TIAP OR TIVAP) AND Occlusion) OR ((TIAP OR
TIVAP) AND (thrombosis OR ‘Thrombosis’[Mesh])) OR
‘Catheter-Related Infections/surgery’[Mesh] OR ‘Catheters,
Indwelling/adverse effects’[MAJR] OR ‘Catheter-Related
Infections/complications’[Mesh]
NOT
hickman OR urinary OR transfemoral OR ‘arterial in-
fusion’ OR microcatheter OR ‘intra-arterial’ OR children
OR pediat* OR paediat* OR neonate OR neonates OR
emergen* OR animal OR dogs OR cats OR cadaver
Study selection
Two independent authors will review all records identi-
fied by the abovementioned search methods. Only
studies meeting the following eligibility criteria will be
included: RCTs as well as prospective and retrospective
OCS and CS providing data on peri- and/or postopera-
tive complications of at least one technique for TIVAP
implantation (OCD and/or CC) predominately for the
treatment of underlying oncological disease in patients
with at least 15 years of age will be regarded as eligible
and suitable for data evaluation. Case reports, trialsinvestigating TIVAP implantation in children, and stud-
ies focusing on patients with non-malignant diseases such
as cystic fibrosis, sickle cell anemia, immunodeficiency
syndrome, and other non-oncological diseases with im-
paired immune or coagulation system will be excluded. If
the title and abstract suggest relevance, the full article will
be assessed for eligibility. Any disagreements between the
two reviewers will be discussed with a third reviewer to
reach consent and to decide which studies to include
for review.Data extraction
A specific sheet for data extraction will be used for the
assessment of the following data from included studies:
author of study, year of publication, country of publica-
tion, language, journal, study duration, study design,
follow-up time and sample size. The baseline data ex-
tracted will be numbers of patients and procedures as
well as participants’ age, sex, and underlying disease. De-
tailed information on the implantation procedures will
comprise performers’ discipline, for example, surgeon or
radiologist, and type of implantation technique including
rescue techniques in the case of OCD and use of ultra-
sound, landmark technique, or fluoroscopic guidance in
the case of CC. Relevant outcome variables will include
perioperative complications, defined as early complica-
tions occurring during the operation or within the first
24 hours after the procedure (hemato-pneumothorax,
early re-intervention due to any cause, early malfunction
of TIVAP, and bleeding), as well as postoperative com-
plications, defined as late complications emerging after
the first 24 hours postoperatively (late malfunction of
TIVAP, ‘pinch off ’ , hematoma, wound infection, late
re-intervention, TIVAP infection, extravasation, TIVAP-
related thrombosis, nerve lesion, TIVAP occlusion,
dislocation of catheter, and hospital re-admission due
to catheter problems). To check that all relevant fields
have been included and to assure that the extraction of
data from different study types will be feasible, the
data extraction form will be piloted by extracting data
from representative articles by two independent re-
viewers. To account for different study designs, several
extraction forms will be developed, if necessary. After
finalizing the document(s) data will be extracted by
two independent reviewers. If there are any disagree-
ments between the two reviewers, a third member of
the working group will be consulted to discuss them.Assessment of the methodological quality of included
studies
According to Loke et al. [12], the methodological quality
of all studies included - independently from study design -
will be assessed by means of a critical appraisal tool
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of adverse effects assessment and its reporting:
1. Are peri- and/or postoperative complications the
main focus of the study?
2. Are clear definitions of complications given?
3. Is the assessment of complications described in
detail?
Risk of bias will be categorized as ‘low’ if all questions
are answered with ‘yes’ , whereas high risk of bias is
assumed if all questions are answered with ‘no’. In all
other cases, risk of bias is classified as ‘moderate’.
Statistical analysis
For each perioperative outcome the event rate with its
95% confidence interval will be derived per intervention
arm and per study. For each postoperative outcome, the
individual follow-up time of each study is taken into
account by calculating an event rate per patient-month
of follow-up. This standardized event rate with its 95%
confidence interval is then used per intervention arm
and per study. Pooled estimates of (standardized) event
rates with corresponding 95% confidence intervals will
be calculated on the base of the Freeman-Tukey double
arcsine transformation [13,14] within a random effect
model framework. Statistical heterogeneity of combined
study results will be assessed by the I2 statistic. Different
study designs, that is, RCTs, OCS, and CS, will be ana-
lyzed separately. Within study design subgroups, add-
itional subgroup analyses will be performed to investigate
potential heterogeneity which might be caused by per-
formers’ discipline, center’s expertise (as regards the
number of implantations per month), or implantation
technique (that is, CC with or without use of ultrasound,
landmark technique, or fluoroscopic guidance and OCD
with or without rescue techniques). Moreover, sensitivity
analyses will be performed in the case of substantial differ-
ences in methodological quality of individual studies as
regards the quality of adverse effects data (see above). The
results will be visualized by forest plots of (standardized)
event rates per intervention arm. The presence of publica-
tion bias will be explored by funnel plots with respect to
the logit (standardized) event rates. Quantitative explor-
ation of publication bias will be performed using Kendall’s
tau and Egger’s regression test. For statistical analysis, the
statistical software R (The R Foundation for Statistical
Computing) with the ‘meta’ package (developed by
G. Schwarzer) will be used.
Discussion
TIVAP implantation is one of the surgical procedures
performed most often in general surgery. The occur-
rence of adverse events and serious adverse events israre for both techniques. However, considering the high
number of TIVAP implantations performed worldwide,
even small differences in complication frequencies be-
tween the two procedures could be of clinical relevance
for patients and health-care systems. A reduction of
peri- and postoperative complications may save costs for
diagnostics, treatments, and hospital admissions due to
complications after TIVAP implantations. Furthermore,
patients may benefit from the prevention of complica-
tions as an earlier start of chemotherapy may be realized
with potential impact on survival and recurrence rates of
oncological diseases (for example, TIVAP-associated
infections inhibit chemotherapy).
This systematic review and proportional meta-analysis
are the first approach to critically appraise and quantify
data on the occurrence of peri- and postoperative com-
plications in patients undergoing OCD compared to CC
for TIVAP implantation. For this purpose, all studies
reporting peri- and/or postoperative complications of at
least one of both techniques will be included independ-
ently of the trial design. Considering the lack of high-
quality trials in surgery and the fact that case series are
the most common trial design in clinical surgical re-
search, case series will also be considered to ensure that
all relevant data will be included [15]. Studies focusing
predominately on patients with non-oncological diseases
will be excluded as this is a minority with relatively rare
underlying diseases which are often associated with spe-
cific elevated risks, for example, increased risk of infec-
tions in patients with immunodeficiency syndrome.
Thus, these subgroups of patients are not considered
representatives for the majority of patients in which
TIVAP implantation is performed. Considering all stud-
ies focusing on patients with malignancies, the pooled
sample size should be large enough to give a good over-
view about the distribution of peri- and postoperative
complications after OCD compared to CC. Furthermore,
because of the relevance and great acceptance of the two
implantation techniques investigated, we expect large
populations in both study groups. Thus, potential
confounding variables such as treatment regimens are
expected to be balanced between both groups and are
not planned to be considered for data extraction.
Assessment of methodological quality will be per-
formed according to the recommendations of Loke et al.
[12] who recently presented a framework for a struc-
tured approach of systematic reviews of adverse effects.
As to date, no appraisal tool for the assessment of meth-
odological quality of studies included in this type of sys-
tematic review has been established; the authors advise
to answer defined questions on the conduct of adverse
events assessment and reporting in all studies included -
independently from study design. In adherence with
Loke et al. [12], application of critical appraisal tools
Klaiber et al. Systematic Reviews  (2015) 4:53 Page 6 of 6commonly used for the assessment of methodological
quality of studies included in systematic reviews which
do not focus on adverse effects is not foreseen, because
available tools such as the Cochrane Collaboration’s tool
for assessing risk of bias in RCTs [16] or the Downs and
Black checklist [17] may mainly apply to the primary
focus of the study which is usually the beneficial effect
of the intervention and not the occurrence of adverse
events. Therefore, even though the methods for the
assessment of the primary endpoint of the study may be
of high quality, the monitoring of harmful effects of the
intervention may be of low quality which may not be
detected with ‘common’ critical appraisal tools.
To date, there is no gold standard for the technique of
TIVAP implantation as evidence for the procedure with
the best benefit/risk ratio is poor. The findings of this
systematic review with proportional meta-analysis will
help to compare peri- and postoperative complication
rates in the two main approaches performed. This may
have influence on daily practice, and data may be imple-
mented in treatment guidelines. Considering the impact
of TIVAP implantation on patients’ well being together
with its socioeconomic relevance, patients will benefit
from evidence-based treatment and health-care costs
may also be reduced.
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